期刊文献+

脂质体递药系统的靶向修饰 被引量:4

Targeting Modification of Liposome Drug Delivery System
下载PDF
导出
摘要 作为药物递送载体,脂质体(LPs)由于免疫原性低、稳定性好、毒性低和成本低而被认为是有前途的纳米药物递送系统。然而,LPs的靶向递送效果并不理想,往往会对正常的机体细胞造成伤害,因此,如何优化LPs药物,使其具有靶向性仍然是当前研究的重点。本文结合近年来国内外相关研究进展,重点介绍了多肽、抗体、糖类、配体,以及核酸适配体等靶向修饰物对LPs功能的影响,并归纳总结了各种靶向修饰目前存在的优势与挑战,以期对LPs给药系统的进一步研究提供科学参考及新药研发提供理论依据。 Liposomes are hollow spheres composed of lipids bilayer membranes,which can encapsulate and deliver hydrophilic and hydrophobic substances.Liposomes are promising nano-drug delivery systems due to low immunogenicity,good stability,low toxicity and cost.Currently,a variety of liposome drugs for tumor treatment have been listed.Liposomes can accumulate in tumor tissues via enhanced permeability and retention effect(EPR)and are internalized into tumor cells by endocytosis or pinocytosis.Subsequently,liposomes are intracellularly cleaved to release drugs,thereby killing tumor cells.Liposomes that rely on the EPR effect are called passive targeting liposomes,which lack the ability to specifically recognize target tissues.However,active targeting liposomes can achieve targeting delivery via the specific binding between the targeting modifiers on the surface of liposomes and receptors on the surface of tumor cells.These receptors such as peptides,carbohydrates,ligands,antibodies and nucleic acid aptamers on the surface of tumor cells overexpress due to rapid growth of tumor cells and needs of nutrients and related growth factors.Thus,liposomes can be reasonably designed according to these specific receptors.Recent years,some studies have reported biomimetic liposomes by coating the cell membrane on the surface of liposomes,however,the research on biomimetic liposomes is still in its infancy,and there are still many problems to be solved.Additionally,since the length is limited,biomimetic liposomes are not reviewed in this paper.Taken together,liposomes as potential drug carriers,not only protect drugs,but also reduce side effects,importantly,they can precisely target tumor tissues through introducing targeting modifiers.In this work,we review the improvement of targeting function of liposome by five targeting modifiers including peptides,carbohydrates,ligands,antibodies and nucleic acid aptamers,and summarize the existing advantages and challenges of various targeted modifications.Finally,this review is expected to provide scientific reference for the LPs drug delivery system study and theoretical basis for the drug development.
作者 杜桑 崔韶晖 陈星妍 张树彪 DU Sang;CUI Shao-Hui;CHEN Xing-Yan;ZHANG Shu-Biao(Key Laboratory of Biotechnology and Bioresources Utilization,Ministry of Education,College of Life Sciences,Dalian Minzu University,Dalian 116600,China)
出处 《生物化学与生物物理进展》 SCIE CAS CSCD 北大核心 2023年第6期1272-1285,共14页 Progress In Biochemistry and Biophysics
基金 国家自然科学基金(21606041)资助项目。
关键词 脂质体 靶向修饰 递药系统 肿瘤 治疗 liposome targeted modification drug delivery system tumor therapy
  • 相关文献

参考文献7

二级参考文献97

  • 1罗岩,兰阳,史济月,王绍宁,张斯杰,刘艳丽,邓意辉.半乳糖化脂质体体外HepG2肝癌细胞的靶向性[J].中国药剂学杂志(网络版),2011(6):119-125. 被引量:3
  • 2王连升,陈颖伟,张建华,李定国,陆汉明.RGD-M6P对原代肝星状细胞的影响[J].上海第二医科大学学报,2005,25(2):112-115. 被引量:2
  • 3赵永德,王晓焕.D-氨基葡萄糖衍生物的研究进展[J].化学研究,2007,18(1):108-111. 被引量:8
  • 4Iyer A K, Khaled G, Fang J, et al. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discovery Today, 2006, 11(17-18): 812-818.
  • 5Greish K J. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target, 2007, 15(7-8): 457-464.
  • 6Nicolas J, Mura S, Brambilla D, et al. Design, functionalization strategies and biomedical applications of targeted biodegradablel biocompatible polymer-based nanocarriers for drug delivery. Chern Soc Rev, 2013,42(3): 1147-1235.
  • 7Weaver M, Laske D W. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM 107) for therapy of malignant gliomas. J Neurooncol, 2003, 65(1): 3- 13.
  • 8Laske D W, Youle R J, Oldfield E H. Tumor regression with regional distribution of the targeted toxin TF-CRM 107 in patients with malignant brain tumors. Nat Med, 1997,3(12): 1362- 1368.
  • 9Theurich S, MaJcher J, Wennhold K, et al. Bergwelt-Baildon, Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. Am Soc Clin Oncol, 2013, 31(5): 59-63.
  • 10Lu Y, Sega E, Leamon C P, et al. Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv Drug Delivery Rev, 2004, 56(8): 1161-1176.

共引文献26

同被引文献60

引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部